Status:

ACTIVE_NOT_RECRUITING

Pancreatic Cancer Early Detection Program

Lead Sponsor:

White Plains Hospital

Conditions:

Pancreatic Cancer

Pancreas Cancer

Eligibility:

All Genders

18+ years

Brief Summary

Early detection testing is recommended for individuals at elevated risk for the development of Pancreatic Cancer. This Protocol will define sufficiently elevated risk as either equal to or greater tha...

Detailed Description

Interested individuals can be referred by physicians, or by family or friends. Individuals are informed that the purpose of this study is to collect outcome data following early detection testing bas...

Eligibility Criteria

Inclusion

  • Any of the following:
  • Known carrier of either the BRCA2 or CDKN2A mutation;
  • Known carrier of any of the following mutations (BRCA1, MLH1, MSH2, PMS2, MSH6, EPCAM , P53, PALB2, APC, or ATM) PLUS first or second degree relative affected with pancreatic cancer;
  • Individual with Peutz-Jeghers Syndrome;
  • Familial Pancreatic Cancer, defined as at least two affected relatives with Pancreatic Cancer, who are first degree relatives with each other, and at least one of those affected must be first degree relative to the study subject;
  • Both parents affected, any age:
  • Any first degree relative diagnosed with pancreatic cancer under age 50;
  • Chronic Pancreatitis Syndrome, defined by either PRSS1 or SPINK1 mutations AND appropriate clinical and family history

Exclusion

  • Any medical condition that contraindicates endoscopy or biopsy
  • Any medical condition that contraindicates MRI
  • Status post partial or complete resection of the pancreas
  • History of pancreatic cancer, either endocrine or exocrine
  • Clinical suspicion of pancreatic cancer, or any previous radiographic or histologic diagnosis of a pre-malignant finding, including IPMN (Intraductal papillary mucinous neoplasm) and PanIN (Pancreatic intraepithelial Neoplasm).
  • diagnosis of dementia
  • Uncontrolled, current illness
  • Renal insufficiency with serum creatinine greater than 2.0 mg/dl

Key Trial Info

Start Date :

April 1 2014

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

June 1 2024

Estimated Enrollment :

100 Patients enrolled

Trial Details

Trial ID

NCT02206360

Start Date

April 1 2014

End Date

June 1 2024

Last Update

May 24 2024

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

White Plains Hospital

White Plains, New York, United States, 10601